{"entity":{"id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","aka":["Mesothelin/FAP Dual-Target CAR-NK Cells"],"tldr":"EB-MF-CAR-NK-01 is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for mesothelioma, aimed at Mesothelin and FAP.","summary":"EB-MF-CAR-NK-01 is a dual-target CAR-NK cell therapy developed by Beijing Biotech. Its targets are Mesothelin and FAP. ClinicalTrials.gov describes the intervention as: Example investigational product: donor-derived allogeneic NK cells engineered to recognize both MSLN-positive tumour cells and FAPpositive stromal elements, manufactured under GMP. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in mesothelioma. The largest, NCT07510815, plans to enrol 36 participants with primary completion expected 2027-03-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of EB-MF-CAR-NK-01","url":"https://clinicaltrials.gov/search?intr=EB-MF-CAR-NK-01"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":[],"targets":["mesothelin","fap"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07510815"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-NK cell therapy","mechanism":"Donor natural killer (NK) cells engineered with chimeric antigen receptors against two targets: mesothelin on mesothelioma cells and fibroblast activation protein (FAP) on the stromal cells around them, as the ClinicalTrials.gov record describes the product.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eb-mf-car-nk-01/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/"}],"trial":[{"id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/"}],"term":[{"id":"cancer-associated-fibroblasts","kind":"term","name":"Cancer-associated fibroblasts (CAFs)","route":"/terms/cancer-associated-fibroblasts/"}]}}